Revenues

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.

Revenues were as follows (in millions):

	Three months ended September 30,
	2023						2022
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	673	$	313	$	986	$	590	$	272	$	862
ENBREL	1,026		9		1,035		1,086		20		1,106
XGEVA	374		145		519		363		132		495
Otezla	462		105		567		529		98		627
Repatha	183		223		406		142		167		309
Nplate	322		97		419		162		126		288
KYPROLIS	231		118		349		217		101		318
Aranesp	107		216		323		128		230		358
EVENITY	214		93		307		136		65		201
Other products(1)	1,099		538		1,637		1,113		560		1,673
Total product sales(2)	$	4,691	$	1,857	6,548		$	4,466	$	1,771	6,237
Other revenues					355						415
Total revenues					$	6,903					$	6,652
	Nine months ended September 30,
	2023						2022
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	1,987	$	954	$	2,941	$	1,783	$	853	$	2,636
ENBREL	2,645		37		2,682		2,965		54		3,019
XGEVA	1,145		440		1,585		1,122		408		1,530
Otezla	1,251		308		1,559		1,366		306		1,672
Repatha	592		626		1,218		461		502		963
Nplate	744		347		1,091		474		364		838
KYPROLIS	699		354		1,053		626		296		922
Aranesp	345		698		1,043		397		676		1,073
EVENITY	570		272		842		376		186		562
Other products(1)	3,424		1,639		5,063		3,379		1,655		5,034
Total product sales(2)	$	13,402	$	5,675	19,077		$	12,949	$	5,300	18,249
Other revenues					917						1,235
Total revenues					$	19,994					$	19,484

____________

(1)    Consists of product sales of our non-principal products as well as sales in prior periods of our divested Bergamo and Gensenta subsidiaries.

(2)    Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2023 and 2022.